The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods

Human and Experimental Toxicology

Volumn 17, Issue 12, 1998, Pages 677-680

  Stewart Davis, A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Action potential duration; Dog; In vitro; In vivo; QT interval

Indexed keywords

ASTEMIZOLE; CISAPRIDE; ERYTHROMYCIN; PROBUCOL; RISPERIDONE; SERTINDOLE; SPARFLOXACIN; TERFENADINE; TERODILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOG; HEART MUSCLE POTENTIAL; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL;

ACTION POTENTIALS; ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032408069     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032798678908134     Document Type: Article

References (28)

1. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Symposium on Cardiac Arrhythmias. Sandoe E, Flenstead-Jensen E, Olsen KH, (eds). AB Astra, Sodertalje Sweden, 1970; 449-472.
2. Estes NAM, Garan H, McGovern B, Ruskin JN. Class I antiarrhythmic agents: classification, electrophysiologic considerations, and clinical effects. In: Mechanisms and Treatment of Cardiac Arrhythmias; Relevance of Basic Studies to Clinical Management. Reiser HJ, Horowitz LN (eds). Urban and Schwarzenberg, Baltimore-Munich, 1985; 183-199.
3. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. American Heart Journal 1987; 113: 1470-1482.
4. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug Reactions and Toxicological Reviews 1994; 13: 77-102.
5. Demolis J-L, Charransol A, Funck-Bretano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. British Journal of Clinical Pharmacology 1996; 41: 499-503.
6. Jackman WM et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Progress in Cardiovascular Diseases 1988; 31: 115-172.
7. Monahan BP et al. Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 1990; 264: 2788-2790.
8. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology 1993; 45: 191-193.
9. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc. Clinical Pharmacology and Therapeutics 1994; 55: 146.
10. Committee for Proprietary Medicinal Products. The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. CPMP 98G/9G European Agency for the Evaluation of Medicinal Products, London, 1996.
11. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Research 1995; 76: 110-119.
12. Adamantidis MM, Lacroix DL, Caron JF, Dupuis BA. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit purkinje fibers: clinical relevance. Journal of Cardiovascular Pharmacology 1995; 26: 319-327.
13. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993; 88: 1832-1844.
14. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarizalion in rabbit purkinje fibers. Fundamental and Clinical Pharmacology 1998; 12: 70-76.
15. Drolet B et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-210.
16. Puisienx FL, Adamantidis MM, Dumotier BM, Dupois BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit purkinje fibres. British Journal of Pharmacology 1996; 117: 1377-1379.
17. Hayashi S et al. Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline. Naunyn-Schmiedeberg's Archive of Pharmacology 1997; 355: 651-658.
18. Natsukawa T et al. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. General Pharmacology 1998; 30: 137-142.
19. Pressler ML et al. In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium. Journal of Cardiovascular Electrophysiology 1995; 6: 443-454.
20. Bluth JD, Lappi MD, Billman GE. Effect of terfenadine on cardiac electrical properties and susceptibility to arrhythmias in animals with healed myocardial infarction. FASEB 1994; 8: A77.
21. Sugiyama A et al. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicology and Applied Pharmacology 1997; 143: 89-95.
22. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Journal of Antimicrobial Chemotherapy 1996; 37: (Suppl A): 161-167.
23. Iida M et al. Four-week oral subacute toxicity study of sparfloxacin in beagle dogs. Chemotherapy (Tokyo) 1991; 39: (Suppl 4): 195-202.
24. Risperidone Summary Basis of Approval. New Drug Application 20-272. Food and Drugs Administration, Washington.
25. Buckley MM-T, Goa KL, Price AH, Brogden RN. Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholestorolaemia. Drugs 1989; 37: 761-800.
26. Marshall FN. Pharmacology and toxicology of probucol. Artery 1982; 10: 7-21.
27. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have lot of potential but a long way to go. Circulation 1990; 81: 686-690.
28. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. Methuen, London, 1959.